Status:
COMPLETED
Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Concussion, Brain
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
The purpose of the study is to learn if Neuraceq™ (Florbetaben F 18 Injection) PET can detect changes in the brains of young athletes who sustained one or more concussions with or without persistent c...
Detailed Description
Former college athletes who sustained at least one previous concussion will undergo computerized neurocognitive testing and a structured questionnaire of present symptoms. \[F-18\] Florbetaben PET ima...
Eligibility Criteria
Inclusion
- 18-40 years of age
- A minimum of 1 concussion prior to study entry
- A minimum of one year post first concussion
- mTBI as defined by the American Congress of Rehabilitative Medicine
- Participants in Cohort A must have either subjective or objective evidence of persistent cognitive deficits
Exclusion
- Impaired decision-making capacity, i.e. inability to provide informed consent
- Pregnancy
- History of other neurologic disorders (e.g., epilepsy, cerebrovascular disease, neurodegenerative disorders, intellectual disability)
- Significant systemic medical illness
- Current DSM-IV Axis I diagnosis of psychiatric illness
Key Trial Info
Start Date :
July 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2019
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05270083
Start Date
July 13 2017
End Date
October 10 2019
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756